share_log

Clearmind Medicine | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

SEC announcement ·  Mar 19 05:22
Summary by Futu AI
Clearmind Medicine Inc., a clinical-stage pharmaceutical company, has filed its annual financial report for the fiscal year ended October 31, 2023. The report details the company's financial position, business developments, and future plans. Financial Performance: Clearmind Medicine reported a net loss of $8,620,837 for the year, with comprehensive loss reflecting the same figure. The company has not generated any revenues and has a negative cash flow from operations of $6,301,472. The accumulated deficit as of October 31, 2023, stands at $18,768,063. Business Development: Clearmind Medicine is focused on the development of psychedelic medicines to address health problems. The company's research and development activities are primarily conducted in Israel. Future Plans: Clearmind Medicine plans to continue its clinical trials and research activities. The company has recently completed a public offering and expects to use the net proceeds to fund its operations and development plans. The company's financial statements have been prepared assuming the continuation of the business as a going concern.
Clearmind Medicine Inc., a clinical-stage pharmaceutical company, has filed its annual financial report for the fiscal year ended October 31, 2023. The report details the company's financial position, business developments, and future plans. Financial Performance: Clearmind Medicine reported a net loss of $8,620,837 for the year, with comprehensive loss reflecting the same figure. The company has not generated any revenues and has a negative cash flow from operations of $6,301,472. The accumulated deficit as of October 31, 2023, stands at $18,768,063. Business Development: Clearmind Medicine is focused on the development of psychedelic medicines to address health problems. The company's research and development activities are primarily conducted in Israel. Future Plans: Clearmind Medicine plans to continue its clinical trials and research activities. The company has recently completed a public offering and expects to use the net proceeds to fund its operations and development plans. The company's financial statements have been prepared assuming the continuation of the business as a going concern.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.